

Contact:

Karen A. Donato, Ph.D.
Executive Vice President, Sales and Marketing
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

***MaxCyte Webinar with Case Studies from ChanTest Corporation:
Improving Large Scale GPCR and Ion Channel Assays***

Gaithersburg, MD, June 15, 2009 –MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, will host case study discussions with industry experts demonstrating how the MaxCyte® STX™ Scalable Transfection System improves transfection of cells with GPCRs, ion channels, and other targets for large scale drug discovery. The technical discussion is open to the industry and will be held by webinar on Tuesday, June 16, from 11:00-Noon EDT.

Dr. John Reardon, formerly Senior Vice President of Discovery Research Biology at GlaxoSmithKline and now Chief Scientific Officer at Cardioxyl Pharmaceuticals, will discuss the importance of effective cell transfections to develop clinically relevant screening assays, and how the MaxCyte STX can reduce bottlenecks and improve the productivity and efficiency of the drug discovery process.

Dr. James Brady, Director of Technical Applications at MaxCyte, will demonstrate how the MaxCyte STX technology enables the rapid, automated, and effective transfection of large numbers of primary cells, cell lines, and stem cells, without requiring efforts to generate stable cell lines. Dr. Brady will show data generated by independent users of the technology comparing the functional activity of cells transfected using the MaxCyte STX versus that of stable cell lines when tested in kinase localization and GPCR assays.

Dr. Barbara Wible, Head of Cell and Molecular Biology at ChanTest Corporation, will describe ChanTest's experience using the MaxCyte STX technology for ion channel assays. ChanTest's case studies with voltage-gated calcium channels and calcium influx assays will demonstrate how the MaxCyte STX technology effectively transfected cells with multiple subunits to create functional ion channel assays suitable for screening.

“We are delighted to present these case studies in cell based assays from users of the MaxCyte STX, and validation of our technology by such renowned industry experts as Dr. Reardon and Dr. Wible of the ChanTest Corporation,” says Mr. Douglas Doerfler, President and CEO of MaxCyte. “Since its recent introduction, the MaxCyte STX Scalable Transfection System continues to be enthusiastically adopted by leading biopharmaceutical companies as an integral part of their drug discovery platform. The MaxCyte STX is proving to become an accepted and valuable tool for reducing the timeline for the development of clinically relevant cell based assays and for accelerating the screening of compound libraries for drug candidate selection.”

To register for the free webinar, visit www.maxcyte.com and click on the registration link. MaxCyte scientists will be available after the webinar to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System. A recording of the webinar will be available on the MaxCyte website after the event.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy, MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte® STX™ Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays and other cell-based applications.

For more information, www.maxcyte.com

###